Partners Richard A. Friedman and Stephen A. Cohen Represent Laidlaw & Company (UK) Ltd. and Roth Capital Partners, LLC as Joint Book Running Managers of PhaseRx, Inc.’s $18.5M IPO
Press Release – New York, NY – May 23, 2016 – Nationally recognized securities and corporate law firm Sichenzia Ross Friedman Ference LLP announced today that it has represented Laidlaw & Company (UK) Ltd. and Roth Capital Partners, LLC as Joint Book-Running Managers of the initial public offering of PhaseRx, Inc. (NASDAQ: PZRX).
The public offering consisted of 3,700,000 shares of the Company’s common stock at a price to the public of $5.00 per share which resulted in aggregate gross proceeds of $18,500,000 before deducting expenses. PhaseRx, Inc. is a preclinical biopharmaceutical company developing a portfolio of orphan drug products for the treatment of inherited enzyme deficiencies in the liver using intracellular enzyme replacement therapy (i-ERT). The Sichenzia Ross Friedman Ference LLP team was led by Partners Richard A. Friedman and Stephen A. Cohen and associate Jay Yamamoto.
Visit SRF's LinkedIn page
Latest posts by Sichenzia Ross Ference LLP (see all)
- Sichenzia Ross Ference LLP Represents HiVentures Zrt., a Hungarian Venture Capital Company, in Private Placement of Series A Preferred Stock of ActiveGraf - January 16, 2020
- Trusts and Estates Attorney - January 13, 2020
- Sichenzia Ross Ference LLP Represents A.G.P./Alliance Global Partners as Sole Placement Agent in $3M Registered Direct Offering of Cellect Biotechnology Ltd. - January 10, 2020